Abiopharma

111, Inc. Announces First Quarter 2026 Unaudited Financial Results

Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®

Alvotech leggur inn að nýju umsóknir um markaðsleyfi í Bandaríkjunum fyrir hliðstæður við Simponi, Simponi Aria og Eylea

Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®

Expro Strengthens Longstanding Partnership With Deployment of Solus™ Technology in the Gulf of America

Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®

Register of shareholders, changes and capital status – exercise of warrants for shares (unlisted) by employees

Shelf offering report for the issuance of BONDS C, according to the shelf prospectus dated 29.8.23, orders: 4.6.26

Change in holdings of interested parties/officers

Examining the possibility of issuing shares and similar warrants in a non-uniform offering, further updates regarding the offering.